INO צמיחה צפויה ברווח נקי למניה השנה Inovio Pharma
A prolonged depletion of cash reserves due to a lack of sales triggered a sharp spike in the annual EPS growth rate, where the figure remains around 50.30. Inovio Pharmaceuticals (INO) maintains a diversified drug portfolio that mitigates regulatory risks, while the creation of a DNA medicine base to combat cancer and viruses lays the foundation for future success, as evidenced by the volatile earnings trend on this chart.
פילוחי מדדים מקיפים ואנליטיקה עבור Inovio (INO)
The monopoly potential of Inovio Pharmaceuticals (INO) is based on a unique DNA vaccine delivery platform, where future pricing power depends directly on the commercialization of patents. By analyzing the year-over-year growth in earnings per share on GURU.Markets, an investor assesses the net income dynamics per share, which allows for the determination of the business's ability to offset inflationary pressure and confirm the fundamental value of the assets.
